Azra Borogovac, MD
Hematology · Irvine, CANPI 1164818639
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,053 of the $20,543 with a category attached, or 78.1%. Johnson & Johnson accounts for 89.5% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $11,968, more than ten times the $401 reported in 2019.
Across 43 payments — averaging $477.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$18K
- Janssen Scientific Affairs, LLC$434
- Amgen$318
- ADC Therapeutics America, Inc.$300
- Lilly USA, LLC$206
- Pfizer$163
- plus $731 from 9 others
Across 5 payments — averaging $25,095 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$125K
- National Marrow Donor Program$742
What the payments were for
- Consulting fees$1,7559%
- Speaking & faculty fees$16,05378%
- Food & beverage$1,9439%
- Education$7934%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 15 | $18,391 |
| Janssen Scientific Affairs, LLC | 4 | $434 |
| Amgen | 4 | $318 |
| ADC Therapeutics America, Inc. | 2 | $300 |
| Lilly USA, LLC | 2 | $206 |
| Pfizer | 2 | $163 |
| Incyte Corporation | 5 | $160 |
| Bristol Myers Squibb | 1 | $156 |
| AstraZeneca | 2 | $143 |
| Seagen Inc. | 1 | $100 |
| Astellas Pharma US Inc | 1 | $95 |
| Sanofi | 1 | $28 |
| Novartis | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $17 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,543 in reported general payments places this provider in the 65th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XospataGilteritinib Fumarate | 12 | $331,425 |
| BrukinsaZanubrutinib | 19 | $277,748 |
| ScemblixAsciminib Hydrochloride | 11 | $239,716 |
| VonjoPacritinib Citrate | 11 | $143,068 |
| VenclextaVenetoclax | 37 | $130,856 |
| DopteletAvatrombopag Maleate | 13 | $96,030 |
| CresembaIsavuconazonium Sulfate | 16 | $94,982 |
| Posaconazole | 12 | $18,401 |
| EliquisApixaban | 20 | $11,713 |
| Acyclovir | 96 | $1,181 |
| Levofloxacin | 24 | $390 |
| Dexamethasone | 24 | $319 |
| Potassium Chloride | 13 | $308 |
| Hydroxyurea | 19 | $193 |
| Prochlorperazine Maleate | 22 | $173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXospata, Cresemba | $95 | $426,40728 claims |
| NovartisScemblix | $18 | $239,71611 claims |
| PfizerEliquis | $163 | $11,71320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 178 hematology providers in California.
Other hematology in Irvine
- Krisstina GowinIrvine$66K
- Everett MeyerStanford$2.1M
- Doris QuonLos Angeles$1.5M
- Amrita KrishnanDuarte$671K
- Ilene WeitzLos Angeles$631K
- Vinod PullarkatDuarte$576K
- Hope RugoSan Francisco$537K
- Alexey DanilovDuarte$407K
- Caroline PiatekLos Angeles$391K
- Deepu MadduriStanford$348K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.